Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
Research & Development
Fate Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fate Therapeutics Inc
NASDAQ:FATE
|
Research & Development
-$116m
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-20%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Research & Development
-$98m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Fate Therapeutics Inc
Glance View
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 449 full-time employees. The company went IPO on 2013-10-01. The firm is focused on the development of programmed cellular immunotherapies for patients with cancer. The company uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The firm's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
See Also
What is Fate Therapeutics Inc's Research & Development?
Research & Development
-116m
USD
Based on the financial report for Sep 30, 2025, Fate Therapeutics Inc's Research & Development amounts to -116m USD.
What is Fate Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-20%
Over the last year, the Research & Development growth was 13%. The average annual Research & Development growth rates for Fate Therapeutics Inc have been 27% over the past three years , -1% over the past five years , and -20% over the past ten years .
